Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

Christie Hospital, Manchester, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Manchester
Treatments:Biologic therapyHospital:Christie Hospital
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This phase I study involved 20 patients with advanced solid tissue cancers, including colorectal (7), ovarian (5), and breast (2). Nine men and eleven women had a median age of 51.5 years.

Treatment: The treatment involved one biological agent: HuMV833. HuMV833 is a recombinant antibody that recognizes vascular endothelial growth factor, which is secreted to promote angiogenesis and tumor growth.

Toxicity: Although one patient with grade-1 hypocalcemia eventually worsened to grade-4, it is unclear whether this was due to treatment. The authors did not observe any grade 3-4 toxicities related to treatment, however, here was one reported grade 3 toxicity for two patients ( asyptomatic prolongation of activated partial thromboplastin time).

Results: Median survival was not reported. No immune response to the antibodies was detected, but a partial response was observed in a patient with ovarian cancer.

Correspondence: Gordon C. Jayson, MD





Back